

## PRESS RELEASE

### Half-Year report on the liquidity contract signed by Lysogene with Kepler Cheuvreux

Paris, France — 11 July 2022 at 06:00 pm — Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform company targeting central nervous system (CNS) diseases, today presents the half-year report on the liquidity contract signed by Lysogene with Kepler Cheuvreux.

Under the liquidity contract concluded by LYSOGENE with the Kepler Cheuvreux brokerage firm, as of 30 June 2022, the following assets were held in the liquidity contract:

- Number of shares: 114,809
- Cash balance: € 60,656.15
- Number of executions on buy side on the second half: 517
- Number of executions on sell side on the second half: 395
- Traded volume on buy side on semester: 239,253 shares for € 227,647.49
- Traded volume on sell side on semester: 178,017 shares for € 178,988.67

As a reminder, as of 31 December 2021, the following assets were held in the liquidity contract:

- Number of shares: 53,573
- Cash balance: € 115,539.70
- Number of executions on buy side on the second half: 224
- Number of executions on sell side on the second half: 216
- Traded volume on buy side on semester: 67,249 shares for € 142,998.52
- Traded volume on sell side on semester: 57,255 shares for € 126,782.42

As a reminder, at the time of the implementation of the liquidity contract, the following assets were held in the liquidity contract:

- Number of shares: 34,030
- Cash balance: € 78,185.94

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June



22<sup>nd</sup> 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.

	Buy Side			Sell Side		
	Number of executions	Number of shares	Traded volume in EUR	Number of executions	Number of shares	Traded volume in EUR
<b>Total</b>	<b>517</b>	<b>239,253</b>	<b>227,647.49</b>	<b>395</b>	<b>178,017</b>	<b>172,988.67</b>
03/01/2022	-	-	-	1	500	975.00
05/01/2022	1	500	975.00	2	1,000	1,990.00
06/01/2022	-	-	-	1	500	1,010.00
07/01/2022	7	500	975.00	-	-	-
10/01/2022	1	500	950.00	-	-	-
13/01/2022	6	2,000	3,660.00	1	500	950.00
14/01/2022	2	500	900.00	-	-	-
17/01/2022	1	500	925.00	4	1,001	1,881.88
18/01/2022	4	1,000	1,880.00	3	499	968.06
19/01/2022	1	500	925.00	-	-	-
20/01/2022	-	-	-	2	500	925.00
21/01/2022	3	1,000	1,810.00	-	-	-
24/01/2022	5	2,000	3,460.00	-	-	-
25/01/2022	3	500	840.00	-	-	-
26/01/2022	3	1,000	1,680.00	1	500	850.00
27/01/2022	5	1,000	1,650.00	1	500	850.00
28/01/2022	5	1,500	2,505.00	-	-	-
31/01/2022	1	500	810.00	-	-	-
01/02/2022	1	500	810.00	2	500	825.00
02/02/2022	3	1,177	1,883.20	-	-	-
03/02/2022	7	2,323	3,391.58	-	-	-
04/02/2022	1	500	700.00	3	1,000	1,480.00
07/02/2022	1	500	775.00	18	6,000	9,960.00
08/02/2022	6	2,000	3,120.00	1	500	825.00
09/02/2022	9	3,000	4,380.00	5	501	761.52
10/02/2022	-	-	-	10	3,999	6,318.42
11/02/2022	4	2,000	3,180.00	6	2,000	3,460.00
14/02/2022	19	8,000	11,520.00	-	-	-
15/02/2022	7	2,000	2,760.00	3	500	715.00
16/02/2022	-	-	-	3	500	705.00
17/02/2022	6	1,500	2,055.00	-	-	-
18/02/2022	5	1,500	2,025.00	1	500	690.00
21/02/2022	6	2,000	2,560.00	2	500	675.00
22/02/2022	3	1,500	1,770.00	-	-	-
23/02/2022	4	1,000	1,170.00	2	500	600.00
24/02/2022	5	1,500	1,650.00	12	5,620	7,025.00
25/02/2022	5	1,000	1,170.00	5	3,000	3,750.00
28/02/2022	-	-	-	6	1,500	1,815.00
01/03/2022	5	2,000	2,320.00	-	-	-
02/03/2022	2	1,000	1,100.00	-	-	-
03/03/2022	2	500	560.00	-	-	-



	Buy Side		
	Number of executions	Number of shares	Traded volume in EUR
<b>Total</b>	<b>517</b>	<b>239,253</b>	<b>227,647.49</b>
04/03/2022	11	4,500	4,635.00
07/03/2022	4	1,500	1,365.00
08/03/2022	1	500	450.00
09/03/2022	-	-	-
11/03/2022	-	-	-
14/03/2022	2	1,000	1,100.00
15/03/2022	3	1,500	1,665.00
16/03/2022	12	4,000	4,600.00
17/03/2022	30	11,000	12,760.00
18/03/2022	14	6,000	6,240.00
21/03/2022	3	1,000	1,010.00
22/03/2022	6	1,500	1,515.00
23/03/2022	6	2,500	2,450.00
24/03/2022	2	1,000	960.00
25/03/2022	5	2,500	2,325.00
28/03/2022	8	3,500	3,220.00
29/03/2022	4	2,000	1,800.00
30/03/2022	8	4,000	3,400.00
31/03/2022	20	8,500	6,545.00
01/04/2022	7	3,501	2,765.79
04/04/2022	-	-	-
05/04/2022	8	3,000	2,490.00
06/04/2022	11	7,050	5,781.00
07/04/2022	-	-	-
08/04/2022	1	1	0.82
11/04/2022	2	1,950	1,579.50
12/04/2022	12	7,000	5,460.00
13/04/2022	15	10,000	8,200.00
14/04/2022	6	4,000	3,080.00
19/04/2022	-	-	-
20/04/2022	1	1	0.79
21/04/2022	7	5,000	4,000.00
22/04/2022	9	3,001	2,310.77
25/04/2022	2	1,000	750.00
26/04/2022	5	2,000	1,500.00
27/04/2022	3	1,500	1,125.00
29/04/2022	2	2,000	1,440.00
02/05/2022	3	3,000	2,100.00
03/05/2022	-	-	-
04/05/2022	-	-	-
05/05/2022	2	1,000	690.00
06/05/2022	4	1,435	990.15
09/05/2022	8	4,000	2,760.00
10/05/2022	8	6,000	3,960.00
11/05/2022	9	3,100	1,984.00

	Sell Side		
	Number of executions	Number of shares	Traded volume in EUR
<b>Total</b>	<b>395</b>	<b>178,017</b>	<b>172,988.67</b>
04/03/2022	-	-	-
07/03/2022	-	-	-
08/03/2022	-	-	-
09/03/2022	5	3,500	3,605.00
11/03/2022	2	1,000	1,080.00
14/03/2022	4	2,500	2,800.00
15/03/2022	-	-	-
16/03/2022	26	8,000	9,520.00
17/03/2022	10	5,000	6,200.00
18/03/2022	1	500	565.00
21/03/2022	-	-	-
22/03/2022	5	383	390.66
23/03/2022	3	113	115.26
24/03/2022	3	1,387	1,400.87
25/03/2022	1	500	470.00
28/03/2022	4	2,000	1,900.00
29/03/2022	5	2,000	1,840.00
30/03/2022	1	500	450.00
31/03/2022	5	1,500	1,245.00
01/04/2022	5	2,632	2,105.60
04/04/2022	8	6,000	4,980.00
05/04/2022	3	2,000	1,720.00
06/04/2022	6	3,000	2,520.00
07/04/2022	4	2,000	1,660.00
08/04/2022	2	1,001	820.82
11/04/2022	1	10	8.20
12/04/2022	-	-	-
13/04/2022	37	18,000	16,020.00
14/04/2022	-	-	-
19/04/2022	3	1,000	780.00
20/04/2022	5	2,001	1,580.79
21/04/2022	16	10,000	8,400.00
22/04/2022	1	1	0.78
25/04/2022	1	1,000	770.00
26/04/2022	1	1,000	770.00
27/04/2022	-	-	-
29/04/2022	-	-	-
02/05/2022	1	100	71.00
03/05/2022	4	1,102	782.42
04/05/2022	1	798	582.54
05/05/2022	1	1	0.72
06/05/2022	3	2,999	2,129.29
09/05/2022	-	-	-
10/05/2022	-	-	-
11/05/2022	1	1,000	660.00



	Buy Side		
	Number of executions	Number of shares	Traded volume in EUR
<b>Total</b>	<b>517</b>	<b>239,253</b>	<b>227,647.49</b>
12/05/2022	1	1,000	650.00
13/05/2022	-	-	-
16/05/2022	2	1,000	660.00
17/05/2022	-	-	-
18/05/2022	1	1,000	710.00
19/05/2022	4	2,029	1,400.01
20/05/2022	-	-	-
23/05/2022	2	2,000	1,380.00
24/05/2022	5	1,001	690.69
25/05/2022	3	2,001	1,380.69
26/05/2022	1	1	0.71
27/05/2022	2	1,000	690.00
30/05/2022	-	-	-
31/05/2022	1	1,000	750.00
01/06/2022	2	2,000	1,540.00
02/06/2022	1	1	0.77
03/06/2022	2	2,000	1,520.00
06/06/2022	7	4,000	3,120.00
07/06/2022	1	1	0.85
08/06/2022	15	10,742	8,486.18
09/06/2022	6	4,000	3,080.00
10/06/2022	3	3,000	2,190.00
13/06/2022	5	3,000	2,130.00
14/06/2022	8	5,000	3,350.00
15/06/2022	4	2,001	1,320.66
16/06/2022	9	7,000	4,410.00
17/06/2022	-	-	-
20/06/2022	2	1,000	630.00
21/06/2022	-	-	-
22/06/2022	1	1	0.70
23/06/2022	5	3,001	2,040.68
24/06/2022	2	150	102.00
27/06/2022	2	1,000	690.00
28/06/2022	-	-	-
29/06/2022	7	4,285	2,870.95
30/06/2022	-	-	-

	Sell Side		
	Number of executions	Number of shares	Traded volume in EUR
<b>Total</b>	<b>395</b>	<b>178,017</b>	<b>172,988.67</b>
12/05/2022	2	1,000	660.00
13/05/2022	4	2,000	1,360.00
16/05/2022	-	-	-
17/05/2022	7	4,840	3,388.00
18/05/2022	5	3,000	2,190.00
19/05/2022	-	-	-
20/05/2022	2	1,000	700.00
23/05/2022	3	2,000	1,400.00
24/05/2022	2	29	20.59
25/05/2022	2	973	690.83
26/05/2022	1	1	0.71
27/05/2022	1	350	248.50
30/05/2022	12	3,650	2,664.50
31/05/2022	4	4,000	3,080.00
01/06/2022	6	2,000	1,560.00
02/06/2022	5	1,253	964.81
03/06/2022	1	748	583.44
06/06/2022	23	13,500	11,340.00
07/06/2022	-	-	-
08/06/2022	-	-	-
09/06/2022	3	1,000	800.00
10/06/2022	-	-	-
13/06/2022	-	-	-
14/06/2022	1	22	15.62
15/06/2022	3	1,111	755.48
16/06/2022	1	903	614.04
17/06/2022	1	1,000	630.00
20/06/2022	5	4,000	2,640.00
21/06/2022	7	4,936	3,455.20
22/06/2022	7	2,001	1,400.70
23/06/2022	2	551	396.72
24/06/2022	4	2,000	1,400.00
27/06/2022	3	519	363.30
28/06/2022	2	482	337.40
29/06/2022	-	-	-
30/06/2022	2	2,000	1,380.00

## About Lysogene

Lysogene is a gene therapy Company focused on the treatment of orphan diseases of the central nervous system (CNS). The Company has built a unique capability to enable a delivery of gene therapies to the CNS to treat lysosomal diseases and other genetic disorders of the CNS. A phase 2/3 clinical trial in MPS IIIA and an adaptive clinical trial in GM1 gangliosidosis are ongoing. Lysogene has also entered into an exclusive worldwide license agreement with SATT Conectus for a gene therapy candidate for the treatment of the Fragile X syndrome, a genetic disease related to autism. [www.lysogene.com](http://www.lysogene.com).

## Forward Looking Statement

This press release may contain certain forward-looking statements, especially on the Company's progress of its clinical trials and cash runway. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice, (ii) factors beyond the Company's control, (iii) clinical trial results, (iv) increased manufacturing costs, (v) potential claims on its products, and (vi) a modification of the terms of its agreements with Sarepta Therapeutics. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "objective," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. A further list and description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorité des Marchés Financiers, including in the 2020 universal registration document, registered with the French Markets Authorities on April 12, 2021, under number D.21-0296, and future filings and reports by the Company. Furthermore, these forward-looking statements are only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. If the Company updates one or more forward-looking statements, no inference should be drawn that it will or will not make additional updates with respect to those or other forward-looking statements.

This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall supersede.

## Contacts

Stéphane Durant des Aulnois  
Chief Financial Officer  
[stephane.durant-des-aulnois@lysogene.com](mailto:stephane.durant-des-aulnois@lysogene.com)  
+ 33 1 41 43 03 99